News

Updates from ASCO2023 – The SONIA Trial

By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center   The CDK 4/6 inhibitors…

1 year ago

Updates from ASCO23 – ADAURA Trial Plenary Lecture

Author:  Lei Deng, MD PGY-6 Fellow Of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY.  Incoming Assistant Professor At UW/Fred Hutch,…

1 year ago

My Take On KEYNOTE-671: ASCO23 June 3, 2023

Author:  Lei Deng, MD PGY-6 Fellow of Hematology/Oncology - Roswell Park Comprehensive Cancer Center, Buffalo, NY.  Incoming Assistant Professor at UW/Fred Hutch,…

1 year ago

Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial

By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center   Findings from the MonarchE clinical trial1 led to the…

1 year ago

A Summary of the DACOTA Trial

By Dr. Chepsy Philip Believer's Church Medical College Hospital   Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the…

2 years ago

Updated Results from the ASCEMBL Trial

By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the…

2 years ago

AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer

By Dr. Dipesh Uprety Karmanos Cancer Institute   Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the…

2 years ago

The Polarix Trial and the Rise of Polatuzumab-RCHP

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center    Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab,…

2 years ago

Risk Factors for Relapse Among Breast Cancer Patients with Pathological Complete Response (pCR) Post Neoadjuvant Treatment

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Attainment of pathological complete response (pCR) of breast cancer is…

2 years ago

Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Endocrine therapy is the mainstay of the management of hormone…

2 years ago